Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719110 | 0.90 | IDH1 (0.42) | MDM2 | |
| SCHEMBL1720881 | 0.87 | PDE4A (0.46) | PDE4APDE4BPDE4DDHODHPDE4C | |
| SCHEMBL1719655 | 0.86 | DYRK1A (0.45) | PDE4APDE4BPDE4DDHODHPDE4C | |
| SCHEMBL1719659 | 0.86 | DYRK1A (0.45) | PDE4APDE4BPDE4DDHODHPDE4C | |
| SCHEMBL1719887 | 0.85 | SLC6A7 (0.40) | PDE4APDE4BPDE4DSLC6A7 | |
| SCHEMBL1719842 | 0.85 | DHODH (0.43) | PDE4APDE4BPDE4DDHODHPDE4C | |
| SCHEMBL1719851 | 0.85 | DHODH (0.43) | PDE4APDE4BPDE4DDHODHPDE4C | |
| SCHEMBL1719864 | 0.81 | PDE4A (0.44) | PDE4APDE4BPDE4DDHODHPDE4C | |
| SCHEMBL1720205 | 0.81 | SLC6A7 (0.37) | PDE4APDE4BPDE4DSLC6A7PIM1 | |
| SCHEMBL1720208 | 0.81 | SLC6A7 (0.37) | PDE4APDE4BPDE4DSLC6A7PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687844-B | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-13 | — | — | CN | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| CN-101687844-A | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | PDE4A 982/4885PDE4B 724/4885PDE4D 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.